Direct answer
Regular sleep/wake times, adequate opportunity and healthy habits can support sleep. Adult chronic insomnia has strong support for multicomponent CBT-I; possible apnea, dangerous sleepiness or injurious nighttime behavior needs assessment. Melatonin evidence differs by indication: historical adult jet lag benefit and weak timed adult delayed-phase guidance do not establish routine chronic-insomnia efficacy. Supplement results and safety depend on exact products, medicines and health context.
- Multicomponent CBT-I has a strong AASM recommendation for adults with chronic insomnia. Sleep hygiene alone has a conditional suggestion against use as the sole treatment; medication decisions require individual assessment (2021 behavioral guideline; Historical 2016 ACP guideline).
- A 2015 review included 20 trials and 1,162 adults, mainly with noncomorbid chronic insomnia. Face-to-face CBT-I improved diary sleep-onset latency by about 19 minutes and wake after sleep onset by 26 minutes; total sleep time was not significantly improved at treatment end (Original meta-analysis).
- Sleep hygiene can be included within CBT-I, but AASM conditionally suggests against using it alone for adult chronic insomnia. This is not proof that every hygiene measure has no effect (Behavioral guideline).
- In a randomized crossover trial of 12 healthy adults, 400 mg caffeine reduced objective total sleep time when taken 0, 3 or 6 hours before bed. This small one-night-per-condition study does not establish a universal safe cutoff (Drake trial).
- Historical trials support short-term melatonin for adult jet lag. AASM 2015 gives a weak suggestion for strategically timed melatonin in adult delayed sleep-wake phase disorder; AASM 2017 weakly suggests against routine melatonin for adult chronic insomnia (Jet lag; Circadian guideline; Insomnia drug guideline).
Table of contents
- Evidence summary
- Reported funding and evidence limits
- What sleep problems are
- Selected sleep problems
- How sleep works
- What works and what does not
- Healthy sleep habits and their limits
- Circadian rhythm: light, timing, exercise, caffeine, screens
- CBT-I: the first-line insomnia treatment
- Sleep apnea and other disorders not to miss
- Supplements for sleep: evidence and safety
- Selected safety issues
- Selected medicine and product precautions
- Who should seek medical care first
- Frequently asked questions
- Sources
Evidence summary
| Claim | Evidence | Primary source | Funding / conflict trace | Strength |
|---|---|---|---|---|
| Healthy adults aged 18–60 should regularly obtain at least 7 hours of actual sleep. | Modified RAND expert consensus; 7–9 hours was judged appropriate. Evidence was largely observational; the upper limit remained uncertain. | AASM/SRS consensus methodology | AASM/SRS and CDC support; multiple authors disclosed commercial research, consulting or device relationships. | Strong consensus; age-specific |
| Multicomponent CBT-I is recommended for adult chronic insomnia. | AASM 2021 gives a strong recommendation. The ACP 2016 recommendation is historical; ACP states its guidelines lapse after five years unless updated. | ACP 2016; AASM 2021 | AASM society funding with managed commercial author ties; ACP operating-budget funding with declared interests and recusals. | Strong |
| Face-to-face CBT-I improves selected diary sleep outcomes. | 20 trials/1,162 adults; pooled latency improved by 19 minutes, wake after sleep onset by 26 minutes. Total sleep time did not significantly improve at treatment end. | Trauer meta-analysis | The review received no funding. Rajaratnam disclosed commercial consulting, research and equipment relationships; included-trial financing was partly tabulated, with gaps (Original author-uploaded paper). | Moderate; selected outcomes |
| Sleep hygiene alone is not recommended for adult chronic insomnia. | AASM gives a conditional suggestion against using it as a single-component therapy; it can remain part of CBT-I. | AASM behavioral guideline | AASM-funded; pharmaceutical/device author relationships and staff employment were disclosed and managed. | Weak for hygiene alone |
| A 400 mg caffeine dose disrupted sleep even 6 hours before bed. | 12 healthy adults; randomized placebo-controlled crossover. Objective total sleep time declined at all three timings; the 6-hour diary duration result was not significant. | Drake trial | Zeo funded the study. Authors disclosed device/pharmaceutical relationships, including a former Zeo vice-president; financing and capsule procurement amounts were unreported (Full original/disclosures). | Moderate; small, high-dose trial |
| Regular exercise has selected subjective sleep benefits. | Xie: 22 RCTs/1,806 adults over 2–12 months; subjective outcomes improved, while most objective duration/latency outcomes did not. Kelley found low/very-low-certainty evidence in selected clinical populations. Neither establishes best clock time. | Xie review; Kelley umbrella review | Xie: Chinese national public grants, no commercial conflicts declared. Kelley: no conflicts declared; dedicated review cash funding not located. Included-trial finances remain incomplete. | Moderate/Weak by outcome |
| Bedtime portable-device use/access is associated with poorer sleep in youth. | Observational review of children/adolescents, mainly ages 10–18; high heterogeneity and low GRADE certainty. No causal brightness-versus-content comparison. | Carter meta-analysis | Partly supported by NICHD R01HD073352 to Hale; four other authors reported no funding. Underlying-study finance is not cleared. | Weak; association |
| Melatonin evidence is indication-specific. | Historical adult jet-lag benefit; weak adult delayed-phase suggestion in AASM 2015. AASM 2017 weakly suggests against routine adult chronic-insomnia use. | Jet-lag review; Circadian guideline; Drug guideline | Cochrane: internal University of Auckland/UK Cochrane Centre support, no external support supplied, Petrie conducted two included trials. AASM guidelines have separate society/author disclosures; full underlying-trial financial chains are not cleared (Original review support/declarations). | Moderate for jet lag; Weak for adult delayed phase |
| Suspected apnea needs an appropriate diagnostic pathway. | PSG or technically adequate home testing for uncomplicated adults at increased risk of moderate-to-severe OSA; negative/inconclusive/inadequate home testing requires PSG. PAP has a strong recommendation for confirmed adult OSA with excessive sleepiness. | Diagnostic guideline; PAP guideline | Diagnostic guideline: AASM-funded, with equipment/pharmaceutical/public-grant relationships. PAP authors disclosed device royalties, Bayer work with recusal, and AASM employment (Diagnostic disclosures; PAP disclosures). | Strong; defined clinical populations |
Reported funding and evidence limits
Research funding at a glance
7 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
| Source | Country / scope | Evidence type | Reported funding / relationships | Evidence limit | Role in this guide |
|---|---|---|---|---|---|
| AASM behavioral guideline | United States; adult chronic insomnia | GRADE clinical guideline | AASM funding; managed pharmaceutical/device author ties and staff employment. | Strong multicomponent CBT-I recommendation; single-component suggestions have lower certainty. Underlying-trial finance varies. | Treatment recommendations, not a blanket conflict-free label. |
| ACP 2016 guideline | United States; adult chronic insomnia | Historical clinical guideline | Exclusive ACP operating-budget funding; interests managed by declarations/recusals, including Manaker spouse’s Pfizer/J&J stock (Full original PDF). | ACP states guidelines expire after five years unless updated. Current CBT-I recommendation here is anchored in AASM 2021. | Historical first-line recommendation; financial interests remain disclosed. |
| Trauer CBT-I meta-analysis | International trials; mainly noncomorbid adult chronic insomnia | 2015 systematic review/meta-analysis | Review unfunded; Rajaratnam commercial consulting, research and equipment relationships disclosed (Original paper). | Inactive comparators, incomplete blinding, subjective diaries; total sleep time result not significant. Trial finance partly reported. | Selected face-to-face CBT-I outcomes, not every delivery format or population. |
| Cochrane jet-lag review | International adult travel trials | Historical 2002 review | Internal academic/Cochrane support; no external support supplied; Petrie authored two included trials (Original review). | Most trial product sources and full financial chains remain unverified; short-term travel outcomes. | Jet lag, not general chronic-insomnia efficacy. |
| JAMA gummy analysis | 25 US gummy products purchased 2022 | Analytical content study | Cohen/Khan disclosed public/nonprofit grants, supplement-related conference support, royalties or prior litigation. Study-specific financing/payment was not reported. | One sample/product; all five CBD-containing products labelled CBD. Not an efficacy or all-lot safety study. | Label-accuracy warning for the tested sample. |
| Ashwagandha sleep review | Five India-based trials/400 unique adults | 2021 meta-analysis | Review unfunded/no competing interests declared; one trial reported partial manufacturer sponsorship and preparations were branded. | Low/moderate certainty varies by outcome; all five original financial chains remain incompletely recovered. | Selected extract outcomes, not proof every product works or is unsafe. |
| NCCIH sleep overview | United States; public guidance | Clinical evidence overview | NIH public-information role; individual contributor and underlying-trial financial chains are not fully supplied. | Overview rather than a new controlled study or financial clearance of cited evidence. | Assessment, safety and cautious treatment context. |
What sleep problems are
Sleep complaints can reflect inadequate sleep opportunity, insomnia, circadian misalignment, breathing disorders, movement disorders or other medical/medicine-related factors. Persistent difficulty despite adequate opportunity needs assessment; severe daytime sleepiness or breathing pauses should be assessed promptly rather than waiting three months. The following table is a selected adult-oriented guide, not a complete diagnostic catalogue (Insomnia overview; Apnea overview; RLS guideline).
Selected sleep problems
| Selected problem | Typical pattern | Assessment or treatment step | Important limit | When to seek care |
|---|---|---|---|---|
| Insufficient sleep opportunity | Work, caregiving or other demands leave too little sleep time. | Protect enough opportunity for actual sleep; the 7-hour consensus applies to healthy adults aged 18–60, not just seven hours in bed (Consensus; Healthy habits). | Needs vary; sedatives do not replace protected sleep opportunity. | Seek assessment if excessive sleepiness persists despite adequate opportunity. |
| Short-term insomnia | Recent difficulty sleeping after stress, illness or schedule change. | Review sleep opportunity, habits and possible contributors; discuss persistent or impairing symptoms with a clinician (Insomnia; Habits). | The adult chronic-insomnia CBT-I guideline is not direct proof of every acute-insomnia self-help recipe. | Do not wait three months when daytime function or safety is impaired. |
| Chronic insomnia | Difficulty initiating/maintaining sleep at least three nights weekly for at least three months, with adequate opportunity and daytime impairment. | Multicomponent CBT-I has a strong recommendation for adults (AASM 2021; Historical ACP 2016). | Sleep hygiene alone has a conditional suggestion against use as sole therapy. | Assessment should include relevant medical conditions, medicines and other sleep disorders. |
| Circadian sleep-wake disorder | Sleep timing differs from the required schedule; delayed/advanced/non-24-hour/irregular patterns require distinction. | Treatment depends on diagnosis, age and timing. AASM 2015 suggestions for light/melatonin are weak and population-specific (Intrinsic-disorder guideline; Sleep-wake cycle). | The cited guideline does not supply one regimen for all circadian or shift-work problems. | Seek care when timing causes sustained functional or safety problems. |
| Suspected obstructive sleep apnea | Loud snoring, breathing pauses/gasping or excessive daytime sleepiness may be clues. | Clinical evaluation and appropriate diagnostic testing (Symptoms; Diagnostic guideline). | Symptoms or questionnaires alone do not establish diagnosis; home testing has defined eligibility and follow-up. | Avoid driving when dangerously sleepy; discuss witnessed breathing pauses promptly. |
| Restless legs / periodic limb movement disorder | RLS: urge to move at rest, worse evening/night and relieved by movement. PLMD is a distinct diagnosis requiring more than reported leg jerks. | For clinically significant RLS, review iron studies, exacerbating medicines and untreated apnea with a clinician (AASM 2025 guideline). | Iron thresholds are RLS-specific consensus guidance; do not self-prescribe iron or assume magnesium treats all leg symptoms. | Seek assessment for persistent sleep disruption or significant distress. |
| Unusual nighttime behavior | Dream enactment with violent movements or injuries warrants assessment; sleepwalking and other parasomnias need distinction. | For RBD, AASM recommends a safer environment: remove dangerous bedside objects and pad sharp edges (AASM 2023 RBD guideline). | RBD recommendations cannot be generalized to every parasomnia or used to self-select sedatives. | New/injurious dream enactment requires clinical evaluation. |
Text version of this infographic
| Selected problem | Pattern | Assessment step |
|---|---|---|
| Not enough opportunity | Protected sleep time is too short. | Allow sufficient opportunity for sleep; individual needs vary (Healthy habits; Adult consensus). |
| Timing mismatch | Sleep occurs too early, late or irregularly. | Seek a diagnosis-specific plan; light/melatonin suggestions depend on age, disorder and timing (Circadian guideline). |
| Persistent insomnia | Difficulty sleeping despite adequate opportunity. | Adult chronic insomnia has strong support for multicomponent CBT-I; restriction needs appropriate assessment and monitoring (Behavioral guideline). |
| Breathing signs | Loud snoring, gasping or witnessed pauses. | Discuss possible apnea and appropriate testing (Apnea symptoms; Diagnostic guideline). |
| Safety concerns | Dangerous daytime sleepiness, injuries or new violent dream enactment. | Avoid sleepy driving and obtain prompt assessment; reduce injury hazards with suspected RBD (Apnea; RBD safety). |
How it works
Sleep involves homeostatic pressure and circadian timing. Adenosine accumulates during waking and caffeine blocks its sleep-promoting signaling; environmental light helps synchronize the brain’s clock. Habits and schedules can influence sleep, but they do not by themselves diagnose or treat every insomnia/circadian disorder. Timed light and melatonin require disorder-specific interpretation (NHLBI sleep-wake cycle; AASM circadian guideline).
Text version of this infographic
Sleep pressure generally rises during waking, while circadian timing changes alertness across the day. Caffeine can block adenosine signaling; light is a clock cue. Healthy habits can support sleep, but clinical circadian treatment requires attention to diagnosis and timing (Sleep-wake cycle; Circadian guideline).
What works and what does not
| Intervention | Verdict | Evidence | Key caveat |
|---|---|---|---|
| Regular sleep/wake times | Supportive habit | NHLBI recommends a consistent sleep/wake schedule (Official guidance). | No cited head-to-head study proves wake time more powerful than bedtime or a schedule alone cures chronic insomnia. |
| Sleep hygiene alone for adult chronic insomnia | Weak as sole therapy | AASM conditionally suggests against using it alone (Guideline). | Can be included within multicomponent CBT-I; not proof every hygiene measure is ineffective. |
| Multicomponent CBT-I | Strong | AASM recommends it for adults with chronic insomnia (2021 guideline; Historical ACP 2016). | Clinician assessment matters; restriction may initially increase sleepiness and is unsuitable for some high-risk contexts. |
| Timed light in selected circadian disorders | Weak; indication-specific | Morning light plus behavior is weakly supported for children/adolescents with delayed phase; evening light for adult advanced phase. Adult delayed-phase light monotherapy had no recommendation (2015 guideline). | Insufficient evidence is not proof of no benefit. Wrong timing and individual safety factors matter. |
| Late caffeine | Moderate; small trial | 400 mg reduced objective sleep time even six hours before bed in 12 adults (Drake trial). | The trial does not establish a safe universal dose or cutoff. |
| Screens / blue-light filters | Weak; association | Youth portable-device and broader electronic-media reviews report associations, not causal optical-versus-content trials (Carter; Han). | They do not prove filters ineffective or that content/notifications matter more than brightness. |
| Alcohol as a sleep aid | Avoid using it as a remedy | NHLBI advises avoiding alcohol before sleep and limiting it in apnea management (Sleep habits; Apnea treatment). | Habit advice is not a quantified risk estimate for every alcohol/medicine/supplement combination. |
| Melatonin | Moderate for jet lag; Weak for adult delayed phase | Historical jet-lag benefit differs from weak strategically timed adult delayed-phase guidance (Jet lag; Circadian guideline). | AASM 2017 weakly suggests against routine adult chronic-insomnia use; no all-indication ranking (Drug guideline). |
| Valerian for adult chronic insomnia | Weak | AASM 2017 weakly suggests against routine use; NCCIH describes inconsistent evidence (Guideline; Valerian). | This is not a head-to-head test against zolpidem or every valerian/hops blend. |
Healthy sleep habits and their limits
Regular schedules, adequate opportunity and a suitable bedroom can support sleep. NHLBI advises healthy habits and follow-up for insomnia; AASM conditionally suggests against sleep hygiene as the sole adult chronic-insomnia treatment. These sources do not prove a checklist prevents every persistent sleep problem (Healthy habits; Living with insomnia; Behavioral guideline).
Practical sleep-habit checklist
- Keep sleep and wake times regular when feasible. This is supportive habit guidance, not a proven standalone chronic-insomnia cure (NHLBI habits).
- Spend time outdoors and be physically active during the day. Clinical bright-light therapy is a separate diagnosis/timing-dependent intervention, with additional safety considerations (NHLBI habits; Light guideline).
- If nighttime sleep is difficult, NHLBI advises limiting naps or keeping them early; its adult guidance suggests short naps, rather than treating all napping as harmful (NHLBI habits).
- Stimulus control within insomnia treatment reserves bed for sleep/intimacy and uses a consistent wake time. Getting out of bed when unable to sleep may need adaptation for falls, mobility limitations or sedative use (AASM behavioral guideline).
- The reviewed CBT-I protocols include avoiding visible clock-checking. This is one protocol element; its isolated causal effect was not established by the meta-analysis (CBT-I review).
- Aim for a comfortable, quiet, cool and dark bedroom as NHLBI advises. Environmental research links light, noise and social/physical conditions with sleep, but much of it is observational rather than proof an individual room change cures insomnia (Habits; Environment review).
- Sleep restriction is a monitored therapeutic protocol, not a general instruction to sleep less. A qualified clinician should assess sleepiness, safety-sensitive work, mania/hypomania and uncontrolled seizures before using it (Behavioral guideline).
Circadian rhythm: light, timing, exercise, caffeine, screens
Light timing
Light helps synchronize circadian timing, and its effects depend on biological timing rather than a universal clock-hour rule. AASM 2015 gives weak, population-specific light/melatonin suggestions; adult delayed-phase light monotherapy had insufficient evidence for a recommendation. Morning light plus behavior in youth and evening light for adult advanced phase are distinct recommendations (Sleep-wake cycle; Circadian guideline).
Exercise timing
Regular exercise improved selected subjective outcomes across varied trials. Xie’s 22 RCTs studied 2–12-month interventions, and most objective sleep-duration/latency outcomes did not improve significantly; Kelley found low/very-low-certainty results in selected populations. These reviews do not establish the best clock time, a universal late-exercise ban or the best modality (Xie review; Kelley review).
Caffeine timing
In 12 healthy adults, one 400 mg caffeine dose reduced objective total sleep time when taken 0, 3 or 6 hours before bed. The 6-hour diary duration change was not significant. This supports caution about late caffeine but cannot set a safe dose/cutoff for every person; its safety findings do not cover pregnancy, arrhythmia or all anxiety disorders (Drake trial; Caffeine/adenosine context).
Screen use
Carter’s youth meta-analysis linked bedtime portable-device access/use with poorer sleep, while Han’s broader review pooled correlational electronic-media studies. Neither isolates a causal blue-light mechanism or compares brightness with content/notification effects. NHLBI recommends a quiet pre-bed period and avoiding bright artificial light; that advice should not be presented as a ranking proven by these observational reviews (Carter; Han; Healthy habits).
Text version of this infographic
- Daytime: support a regular sleep/wake schedule, time outdoors and physical activity (Healthy habits).
- Later day: avoid late caffeine; if naps interfere with nighttime sleep, keep them short and early. The cited small caffeine trial does not establish a universal six-hour safe interval (Habits; Caffeine trial).
- Before bed: allow a quiet routine and reduce bright artificial light. These habits can support sleep but do not replace assessment of persistent insomnia (Habits; Insomnia).
- At night: keep the room comfortable, dark and quiet. Stimulus-control instructions should be adapted for falls, mobility limitations or sedative use (Habits; Stimulus control).
CBT-I: the first-line insomnia treatment
AASM 2021 strongly recommends multicomponent CBT-I for adults with chronic insomnia. Protocols combine behavioral/cognitive elements and require assessment of relevant risks. The ACP 2016 initial-treatment recommendation is historical; current advice here is anchored in the 2021 guideline (AASM 2021; Historical ACP 2016).
Core CBT-I components
| Component | What it does | Example | Safety caveat |
|---|---|---|---|
| Stimulus control | Reassociate bed with sleep. | Go to bed when sleepy, reserve bed for sleep/intimacy, and use a consistent wake time within the treatment plan (Guideline/Table 3). | Leaving bed when unable to sleep needs adaptation for fall risk, mobility limits or sedative use. |
| Sleep restriction | Reduce excessive awake time in bed through a monitored protocol. | A clinician uses sleep information to adjust time in bed; this is not an instruction to deprive oneself of sleep (Guideline). | May be unsuitable with safety-sensitive driving/work, excessive sleepiness, predisposition to mania/hypomania or poorly controlled seizures. |
| Cognitive components | Address beliefs and worry that maintain insomnia. | Explore catastrophic sleep expectations within multicomponent CBT-I; this is not a guaranteed isolated cure (Behavioral guideline). | Persistent or severe mental-health symptoms need appropriate clinical care. |
| Relaxation training | Reduce arousal as an insomnia intervention. | Abdominal breathing, progressive muscle relaxation and imagery are examples. AASM gives relaxation a conditional suggestion with low-certainty evidence (Guideline). | The guideline made no recommendation for standalone mindfulness because evidence was insufficient; this does not prove no benefit. |
| Sleep-hygiene education | Address habits and environmental contributors. | Regular schedules and a suitable bedroom may be included within CBT-I (Habits; Guideline). | AASM conditionally suggests against hygiene alone for adult chronic insomnia. |
Text version of this infographic
Multicomponent CBT-I uses combinations of behavioral/cognitive elements; protocols do not all require exactly the same five components. AASM strongly recommends it for adults with chronic insomnia, while restrictions and stimulus-control steps require appropriate safety assessment (Guideline and intervention definitions).
Sleep apnea and other disorders not to miss
Snoring, gasping or witnessed breathing pauses can justify apnea assessment but do not establish diagnosis. AASM recommends PSG or technically adequate home testing for uncomplicated adults at increased risk of moderate-to-severe OSA; negative, inconclusive or inadequate home testing requires PSG. Complex conditions may require PSG from the outset. PAP has a strong recommendation for confirmed adult OSA with excessive sleepiness; it is not a general proof of reduced cardiovascular mortality in every nonsleepy patient (Apnea overview; Diagnostic guideline; PAP guideline).
Supplements for sleep: evidence and safety
Supplement results depend on diagnosis, preparation, population and outcome. Historical melatonin trials support adult jet lag; adult delayed-phase guidance is weak and timing-specific. Selected magnesium, glycine, tart-cherry, theanine and ashwagandha studies have substantial limits and do not establish a best supplement. Adult chronic insomnia has a strong recommendation for multicomponent CBT-I (Jet lag; Circadian; CBT-I; Complementary approaches).
| Supplement | Studied use | Evidence limit | Reported funding / relationships | Selected safety information |
|---|---|---|---|---|
| Melatonin | Historical adult jet lag; strategically timed adult delayed phase (Jet lag; Circadian). | Moderate for jet lag; Weak adult delayed-phase suggestion. AASM 2017 weakly suggests against routine adult chronic-insomnia use. | Cochrane review: internal support, no external support supplied; Petrie authored two trials. Full trial financial chains remain unverified (Original review). | Short-term drowsiness/headache/dizziness/nausea; long-term and pediatric safety uncertain. Epilepsy or blood-thinner use requires medical supervision; discuss pregnancy/lactation and child use (NCCIH). |
| Magnesium | A 2021 review included 3 RCTs/151 older adults (Original review). | Low/very-low certainty; latency signal in 2 studies/55 people, total sleep time nonsignificant. Does not prove low-status insomnia benefit or a best form. | Review reported no specific grant/no competing interests; public/academic support acknowledged. Complete trial finance remains unverified. | GI effects and kidney-risk precautions; medicine/supplement elemental intake matters. Antibiotic/bisphosphonate spacing should follow exact label or prescriber guidance (NIH ODS). |
| Glycine | 3 g in 7 analyzed healthy sleep-restricted employees over 3 nights (Human study). | Selected fatigue/vigilance signals; not a chronic-insomnia trial. | Ajinomoto employee authors; partial public PROBRAIN support. Product payment terms unreported. | Longer-term 3 g sleep-use safety is not established here. The cited 30 g/day clozapine-treated schizophrenia trial had no benefit and possible antagonism; it does not establish 3 g bedtime interaction or AE rates (Different-dose/population abstract). |
| Valerian | Selected adult chronic-insomnia studies and guidance (AASM 2017; NCCIH). | Weak; AASM suggests against routine use. This is not proof every valerian/hops blend fails. | Products/studies vary; the guideline has society/author disclosures and does not clear all trial financing. | Headache, GI upset, mental dullness and vivid dreams reported; possible alcohol/sedative combination risk, uncertain long-term safety (NCCIH). |
| Tart cherry | Two 2-week crossover pilots: 15 and 8 analyzed older insomnia adults (Pigeon; Losso). | Weak; selected diary/PSG signals, with other outcomes nonsignificant. Exact juice preparations differ. | CherryPharm funded/supplied Pigeon product; Cherry Marketing Institute supported/supplied Losso product, with public center support. Amounts/agreements unknown. | Small samples cannot establish long-term safety, interaction rates or equivalence of all juices/extracts. |
| L-theanine | A 28-day 400 mg/day AlphaWave trial in 30 healthy moderately stressed adults (Original trial). | Weak for a sleep benefit: PSQI did not improve versus placebo; actigraph time asleep decreased. Sleep disorders were excluded. | Ethical Naturals funded study/publication; company and KGK employee-author roles disclosed. | Two possibly related mild dry-mouth/metallic-taste events; this is not comprehensive safety or interaction evidence. |
| Ashwagandha | Five RCTs/400 unique adults using branded extracts over 6–12 weeks (Review). | Low/moderate certainty varies by outcome; no clear pooled PSQI/TIB/QoL advantage. Different clinical populations are not interchangeable. | Review unfunded/no competing interests; one trial partly manufacturer sponsored. All five original financial chains remain incomplete. | Drowsiness/GI effects and rare liver injury; avoid pregnancy/lactation and advanced liver disease. NCCIH cautions about thyroid/autoimmune disease and selected medicines (NCCIH; LiverTox). |
Text version of this infographic
- Indication-specific: historical adult jet lag benefit differs from a weak, timed adult delayed-phase suggestion (Jet lag; Circadian guideline).
- Limited clinical evidence: older-adult magnesium findings, selected glycine fatigue/vigilance results and two small tart-cherry pilots do not establish a best insomnia treatment (Magnesium; Glycine; Cherry pilot; Cherry pilot).
- Disclosed finances matter: theanine and cherry examples have commercial funding/product relationships; the ashwagandha review reports one partly sponsored trial. Sponsorship alone does not establish whether a result is valid (Theanine; Cherry; Cherry; Ashwagandha).
- Important limits: AASM weakly suggests against routine valerian for adult chronic insomnia. The reviewed homeopathy case and fixed-order volunteer study cannot establish efficacy; gummy-content testing is not an efficacy test of all blends (Valerian guidance; Homeopathy case; Fixed-order study; Gummy analysis).
Selected safety issues
| Intervention / ingredient | Reported effects / limits | Serious warnings / uncertainty | Relevant contexts | Source |
|---|---|---|---|---|
| CBT-I sleep restriction | Early sleepiness, fatigue, irritability or concentration difficulty may occur. | May be unsuitable for high-risk driving/work, excessive sleepiness, mania/hypomania predisposition or poorly controlled seizures. | Clinician assessment/monitoring; stimulus-control mobility/fall adaptations may be needed. | AASM 2021 |
| Clinical bright-light therapy | Headache, eyestrain, nausea or agitation can occur; exact disorder-specific rates are not supplied. | Guideline harms discussion includes hypomania and migraine/photosensitivity concerns, largely from evidence outside circadian trials. | Bipolar disorder, eye disease or photosensitizing medicines require professional assessment; ordinary daytime outdoor activity is a separate habit. | AASM 2015 |
| Caffeine | The cited trial demonstrated objective sleep loss after 400 mg, including six hours before bed. | It did not comprehensively assess arrhythmia, pregnancy or other high-risk adverse-event rates. | 12 healthy adults; no universal dose/cutoff or broad safety clearance. | Drake trial |
| Melatonin | Short-term headache, dizziness, nausea and drowsiness reported. | Long-term and pediatric safety remain uncertain; uncertainty is not proof of endocrine harm. | Epilepsy, blood thinners, pregnancy/lactation and child use warrant medical advice. | NCCIH |
| Magnesium | Supplemental magnesium can cause diarrhea, nausea or cramping. | Very high intake can cause toxicity, including hypotension, breathing difficulty and rhythm problems; risk rises with impaired kidney function. | Count supplements/medicines. Adult 350 mg supplemental/medicine UL excludes food and physician-supervised treatment; it is not a safety guarantee. | NIH ODS |
| Valerian | Headache, GI upset, mental dullness, excitability and vivid dreams reported. | Very rare liver-injury reports often involve combinations; long-term safety is unknown. | Possible alcohol/sedative risk; pregnancy/lactation evidence insufficient. Do not generalize to all hops products. | NCCIH |
| Ashwagandha | Drowsiness, stomach upset, diarrhea and vomiting. | Rare clinically apparent liver injury; severe outcomes reported especially with preexisting liver disease. | Avoid pregnancy/lactation and cirrhosis/advanced liver disease; thyroid/autoimmune and medicine precautions require review. | NCCIH; LiverTox |
| CBD sleep products | Prescription/high-dose studies report sedation, GI effects and appetite changes; retail-dose rates are not established. | Dose-related liver risk, especially with valproate; clobazam exposure and selected drug interactions are documented. Warfarin evidence includes a high-dose case. | Do not infer retail-gummy safety or insomnia efficacy from a seizure-product label. | Clinical chapter; Human toxicity review; Current prescribing label |
Selected medicine and product precautions
| Ingredient / medicine context | Evidence or precaution | Limit | Clinical interpretation | Source |
|---|---|---|---|---|
| Melatonin / combinations | Drowsiness and product-combination concerns. | These sources do not establish a clinical respiratory-interaction rate with every sedative, opioid or sleep product. | Ask a clinician/pharmacist about the exact combination and avoid driving when sedated. | Melatonin; Sleep products |
| Melatonin / blood thinners | NCCIH advises medical supervision. | This does not prove the same bleeding risk for every DOAC, antiplatelet or dose. | Discuss the actual medicine before supplement use. | NCCIH |
| Melatonin / medically managed blood pressure | NHLBI notes melatonin can affect blood pressure. | This is not an interaction trial covering every antihypertensive or diabetes medicine. | Discuss medically managed conditions and medicines with the treating clinician. | NHLBI insomnia treatment |
| Magnesium / tetracycline or quinolone antibiotics | Binding can reduce antibiotic absorption. | Intervals depend on the exact medicine and instructions. | Follow the medication label and prescriber/pharmacist spacing instructions. | NIH ODS |
| Magnesium / oral bisphosphonates | Magnesium products can reduce absorption. | The exact medicine’s dosing requirements control. | Follow its label/prescriber instructions; do not improvise a universal mineral schedule. | NIH ODS |
| Magnesium / diuretics or long-term PPIs | Loop/thiazide drugs can increase magnesium loss; potassium-sparing drugs reduce loss. Long-term PPI use can cause low magnesium. | These mechanisms do not determine an individual supplement dose. | Have the clinician review medicines and whether assessment is needed. | NIH ODS |
| Valerian / alcohol or sedating medicines | NCCIH cautions about possible additive sleep-inducing effects. | Not a quantified interaction estimate for every hops blend, antihistamine or opioid. | Avoid combining without professional advice. | NCCIH |
| Ashwagandha / sedatives | NCCIH lists possible medicine interactions. | Specific product/dose clinical interaction rates are not supplied. | Discuss the exact medicine before combining. | NCCIH |
| Ashwagandha / thyroid disease or medicines | NCCIH cautions about thyroid disorders and hormone medicines. | Not proof every preparation causes the same thyroid effect. | Seek treating-clinician review before use. | NCCIH |
| CBD / selected prescription medicines | The pharmaceutical label details clobazam/everolimus exposure, valproate-related liver risk and possible CNS-depressant effects. | Do not convert metabolic lists into proven clinical risks for every antidepressant, immunosuppressant or retail dose. | A clinician/pharmacist should review the exact products, medicines and liver context. | Current label; Human review |
Who should seek medical care first
Obtain prompt assessment for witnessed breathing pauses, dangerous daytime sleepiness, persistent insomnia despite adequate opportunity or new/injurious dream enactment. Avoid driving when dangerously sleepy; urgent symptoms such as chest pain, fainting or suicidal thoughts need urgent care. Before sleep restriction or supplement use, discuss relevant medicines, pregnancy and medical conditions with a clinician. Do not wait three months when safety is impaired (Apnea symptoms; RBD safety; Restriction risks; Supplement/assessment guidance).
Frequently asked questions
What is recommended for adult chronic insomnia?
Multicomponent CBT-I has a strong AASM 2021 recommendation for adults with chronic insomnia. Assessment should distinguish inadequate opportunity, other sleep disorders and medical contributors. The ACP 2016 initial-treatment recommendation is historical; these sources do not establish the fastest cure for every sleep complaint (AASM 2021; Historical ACP 2016; Assessment).
Is sleep hygiene enough for chronic insomnia?
AASM conditionally suggests against sleep hygiene alone for adult chronic insomnia. It can still be part of CBT-I; the recommendation does not establish that every hygiene measure has no benefit (Guideline).
Does melatonin help sleep?
It depends on the indication. Historical trials support short-term adult jet lag, while AASM 2015 gives a weak strategically timed adult delayed-phase suggestion. AASM 2017 weakly suggests against routine adult chronic-insomnia use; none of these findings ranks melatonin best for every sleep problem (Jet lag; Circadian guideline; Drug guideline).
How late is too late for caffeine?
A 400 mg dose reduced objective total sleep time even six hours before bed in 12 healthy adults. The small crossover trial does not identify a universal safe interval or dose; six hours should not be treated as guaranteed safe (Drake trial).
Are screens bad because of blue light only?
The cited studies cannot isolate one cause. Carter pooled observational youth device studies, and Han broader correlational media studies. Light, arousal and time displacement are proposed routes, but these reviews do not establish which dominates or prove a filter-versus-content strategy superior. NHLBI advises a quiet, dimmer pre-bed period (Carter; Han; Healthy habits).
What are signs that it might be sleep apnea?
Loud snoring, breathing pauses, gasping, dry mouth, morning headache or daytime sleepiness can prompt discussion with a clinician. Symptoms alone do not diagnose apnea. AASM’s home-test pathway is for selected uncomplicated adults at increased risk of moderate-to-severe OSA; a negative/inadequate/inconclusive result requires PSG (Symptoms; Diagnostic guideline).
Is magnesium a good sleep supplement?
A 2021 review of 3 RCTs/151 older adults found low/very-low-certainty evidence, with a sleep-onset signal but no significant total-sleep-time improvement. It does not establish a best form or prove low-status people obtain insomnia benefit. Correcting inadequate intake is a separate nutritional role; kidney, GI and medicine precautions matter (Original review; NIH ODS).
Can exercise close to bedtime ruin sleep?
The cited reviews concern regular exercise interventions, not a universal last-workout cutoff. Xie included 2–12-month programs and found mainly subjective benefits; Kelley’s selected-population umbrella review had low/very-low-certainty evidence. They do not prove the best clock time or a blanket late-exercise rule (Xie; Kelley).
Sources
- Watson et al. Joint AASM/SRS adult sleep-duration consensus: methodology and discussion (2015).
- Qaseem et al. ACP adult chronic-insomnia guideline (historical 2016). Original full PDF and declarations.
- Edinger JD, et al. Behavioral and psychological treatments for chronic insomnia disorder in adults: AASM guideline. PMC
- Trauer et al. CBT-I for chronic insomnia: systematic review/meta-analysis (2015). Original author-uploaded main paper.
- Sateia MJ, et al. AASM pharmacologic treatment guideline for chronic insomnia. PubMed
- Herxheimer/Petrie. Melatonin for prevention/treatment of jet lag (historical 2002 review). Original full review/support/declarations.
- Auger RR, et al. AASM circadian rhythm sleep-wake disorders guideline. PMC
- Kapur VK, et al. AASM diagnostic testing guideline for adult OSA. PubMed
- Patil SP, et al. AASM PAP treatment guideline for adult OSA. PubMed
- Drake C, et al. Caffeine effects on sleep taken 0, 3, or 6 hours before bed. PubMed
- Kelley GA, Kelley KS. Exercise and sleep: a systematic review of previous meta-analyses. 2017. Research record
- Xie Y, et al. Exercise effects on sleep quality and insomnia. PMC
- Carter B, et al. Portable screen-based media device use and sleep outcomes. PMC
- Billings ME, et al. Physical and social environment relationship with sleep. PMC
- NCCIH. Sleep Disorders and Complementary Health Approaches. NCCIH
- NCCIH. Melatonin: What You Need To Know. NCCIH
- NIH Office of Dietary Supplements. Magnesium Fact Sheet. NIH ODS
- NCCIH. Valerian: Usefulness and Safety. NCCIH
- NCCIH. Ashwagandha. NCCIH
- LiverTox. Ashwagandha. NCBI Bookshelf
- Sleep Foundation/Sleep Doctor. Sleep hygiene: commercial secondary overview, not an efficacy trial. Ownership/editorial relationship. NHLBI healthy sleep habits. NHLBI insomnia treatment. AASM 2025 RLS/PLMD guideline. AASM 2023 RBD guideline.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.